Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will announce its fourth quarter 2020 financial results on March 15, 2021, after market close. A conference call is scheduled for 2:00 PM PT to discuss the results. Amphastar specializes in developing and selling generic and proprietary injectable and inhalation products used primarily in hospital settings. The announcement includes forward-looking statements regarding financial performance, market growth, and the potential impacts of COVID-19 on operations.

Positive

• Upcoming financial results announcement may bolster investor interest.
• Specializes in high-barrier-to-entry pharmaceutical products enhancing market positioning.

Negative

• Uncertainties related to COVID-19 could negatively impact operations and demand.
• No financial metrics or guidance provided in the announcement.

RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.

The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.

Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.

Contact:

William J. Peters
Chief Financial Officer
(909) 980-9484

FAQ

When will Amphastar Pharmaceuticals announce its Q4 2020 results?

Amphastar Pharmaceuticals will announce its Q4 2020 results after market close on March 15, 2021.

What time is the conference call for Amphastar Pharmaceuticals' Q4 results?

The conference call is scheduled for 2:00 PM Pacific Time on March 15, 2021.

How can I access the Amphastar Pharmaceuticals conference call?

You can access the conference call by dialing (877) 407-0989 for toll-free calls or (201) 389-0921 for international calls, starting five minutes before the call.

What products does Amphastar Pharmaceuticals focus on?

Amphastar primarily develops and sells generic and proprietary injectable and inhalation products, often used in hospital or urgent care settings.

What are the forward-looking statements in Amphastar's press release?

The forward-looking statements include expectations about financial performance, market size, product launches, and potential impacts from COVID-19.